AstraZeneca
|
AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion dollar healthcare business with 12,200 employees committed to improving people's lives. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.
More from Zoominfo » |
AstraZeneca looks to sell FluMist in Europe
Drug maker AstraZeneca submitted a new drug application with European Union authorities to market a nasal spray vaccine against the flu, the company said Tuesday.
From The News Journal - 1 day ago
Company seeks approval for nasal spray flu vaccine
Drugmaker AstraZeneca submitted a new drug application with European Union authorities to market a nasal spray vaccine against the flu, the company said Tuesday. The marketing application has been submitted to the European Medicines Agency. The submission is...
From San Francisco Chronicle - 3 days ago
More news from Yahoo! News
|
|
AstraZeneca in treatment setback - Humber Business
Panmure Gordon's Tom Kemp said the FDA's decision "represents another setback for the company's pipeline" although Seroquel still represented a "major opportunity" for AstraZeneca. But he added: "We hope the company will be able to ...
From
HumberBusiness.co.uk News Feed...
- 15 days ago
Bristol-Myers Squibb Company , AstraZeneca PLC Expand Diabetes Tie ...
The companies now have agreed to co-develop dapagliflozin in Japan with AstraZeneca having operational and cost responsibility for all development and regulatory activities on behalf of the collaboration. The two companies will jointly ...
From
Biospace.com Featured News
- 30 days ago
On Biostatistics and Clinical Trial: AstraZeneca considers ...
In an interview published last week by the Financial Times, AstraZeneca CEO David Brennan said the company was studying the launch of biosimilar products, although he said such a move would depend on the legislation being considered by ...
From
On Biostatistics and Clinical ...
- by Web blog from Dr. Deng - 8 days ago
More blog posts from Google Blog Search
|
|